Immune Response Analysis to Influenza Vaccine in Elderly Aged Over 65 Years (Expand IDWP21)
Recruitment status was Recruiting
This study is the first step in a clinical research program that aims to study the immune response to influenza vaccine in the elderly and then to propose a new method of administering the vaccine.
Influenza can cause severe complications in patients at risk (elderly and subjects vulnerable because of a chronic underlying disease). Over 90% of deaths related to influenza occur in people aged over 65 years.
Vaccination is the most effective way to prevent infection. The World Health Organization recommends annual immunization for people at risk, including all persons aged over 65 years, to reduce the risk of morbidity and mortality related to influenza.
However, the immune response to influenza vaccine appears to be lower in elderly than in young people.
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
|Official Title:||Immune Response Analysis to Influenza Vaccine in Elderly Aged Over 65 Years|
- antibody rates after influenza vaccination [ Time Frame: up to 3 months after vaccination ] [ Designated as safety issue: No ]
|Study Start Date:||November 2010|
|Estimated Study Completion Date:||April 2012|
|Estimated Primary Completion Date:||April 2012 (Final data collection date for primary outcome measure)|
|Experimental: antibody rates||
Procedure: Blood sample
Blood sample of 7 ml
Please refer to this study by its ClinicalTrials.gov identifier: NCT01289535
|Contact: Catherine GOUJON, Dr||+33 478 86 41 email@example.com|
|Unité de Recherche Clinique en Immunologie Lyon Sud (URCI-LS) et Service d'Immunologie clinique et allergologie||Recruiting|
|Pierre-Bénite, France, 69495|
|Contact: Catherine GOUJON, Dr +33 478 86 41 25 firstname.lastname@example.org|
|Principal Investigator: Catherine GOUJON, Dr|